INIBIDORES DE SGLT2 NA CARDIOMIOPATIA CHAGÁSICA CRÔNICA: RACIONAL FISIOPATOLÓGICO, LACUNAS DE EVIDÊNCIA E PERSPECTIVAS TERAPÊUTICAS
DOI:
https://doi.org/10.36557/2674-8169.2026v8n11p1468-1488Palavras-chave:
Cardiomiopatia Chagásica, Doença de Chagas, Inibidores do Transportador 2 de Sódio-Glicose, Insuficiência Cardíaca, Doenças NegligenciadasResumo
RESUMO
Introdução: a cardiomiopatia chagásica crônica (CCC) é uma das principais causas de insuficiência cardíaca (IC) na América Latina e tem prognóstico pior que o de outras etiologias, mas foi pouco representada nos ensaios que estabeleceram os inibidores do cotransportador sódio-glicose tipo 2 (iSGLT2) como terapia fundamental da IC. Objetivo: sintetizar criticamente o racional fisiopatológico e as evidências disponíveis sobre o uso de iSGLT2 na CCC, identificar lacunas e propor uma agenda de pesquisa. Metodologia: revisão narrativa com busca estruturada no PubMed/MEDLINE, realizada em 1º de novembro de 2026 e complementada por diretrizes, revisões sistemáticas e busca manual de referências. A qualidade da evidência foi classificada quanto à proximidade com a pergunta clínica (direta, indireta ou mecanística). Resultados: a estratégia que combinou iSGLT2 e doença de Chagas recuperou 13 registros, dos quais apenas dois abordavam o tema: uma carta que propõe hipótese antiarrítmica e um registro observacional no qual um subgrupo chagásico tratado com terapia quádrupla apresentou resultados na mesma direção da coorte geral. Não foram identificados ensaios clínicos, coortes específicas nem estudos experimentais com infecção por Trypanosoma cruzi. Em contrapartida, há convergência plausível entre os mecanismos da CCC (inflamação persistente, fibrose, arritmogênese, disfunção mitocondrial, distúrbios autonômicos e microvasculares) e os efeitos descritos para os iSGLT2, sustentados sobretudo por estudos experimentais em outros modelos e por análises de grandes ensaios em populações não chagásicas. A diretriz brasileira de 2023 atribui à indicação nível de evidência B, de natureza indireta, com recomendação ponderada. Os ensaios recentes com sacubitril/valsartana na CCC, que mostraram redução de peptídeos natriuréticos sem diferença significativa em desfechos clínicos, indicam que a transposição de resultados entre etiologias não deve ser presumida. Conclusão: o uso de iSGLT2 na CCC com fração de ejeção reduzida é biologicamente plausível e sustentado por evidência indireta robusta, mas carece de demonstração direta. Ensaios dedicados, estudos mecanísticos com desfechos arrítmicos e de fibrose miocárdica e modelos experimentais de infecção crônica são prioridades.
Palavras-chave: Cardiomiopatia Chagásica; Doença de Chagas; Inibidores do Transportador 2 de Sódio-Glicose; Insuficiência Cardíaca; Doenças Negligenciadas.
Downloads
Referências
1. Marin-Neto JA, Rassi A Jr, Oliveira GMM, Correia LCL, Ramos Júnior AN, Luquetti AO, et al. SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease – 2023. Arq Bras Cardiol. 2023;120(6):e20230269. doi:10.36660/abc.20230269
2. Martins-Melo FR, Ramos AN Jr, Alencar CH, Heukelbach J. Prevalence of Chagas disease in Brazil: a systematic review and meta-analysis. Acta Trop. 2014;130:167-74. doi:10.1016/j.actatropica.2013.10.002
3. Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82-94. doi:10.1016/S0140-6736(17)31612-4
4. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018;138(12):e169-e209. doi:10.1161/CIR.0000000000000599
5. Bonney KM, Luthringer DJ, Kim SA, Garg NJ, Engman DM. Pathology and pathogenesis of Chagas heart disease. Annu Rev Pathol. 2019;14:421-47. doi:10.1146/annurev-pathol-020117-043711
6. Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, et al. Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail. 2017;10(11):e004361. doi:10.1161/CIRCHEARTFAILURE.117.004361
7. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol. 2017;70(12):1510-24. doi:10.1016/j.jacc.2017.08.004
8. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med. 2015;373(14):1295-306. doi:10.1056/NEJMoa1507574
9. Martí-Carvajal AJ, Kwong JSW. Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. Cochrane Database Syst Rev. 2016;7(7):CD009077. doi:10.1002/14651858.CD009077.pub3
10. Ramírez-Olivencia G, Muñoz Nieto C, Fernández Tomás M, Martí Sánchez D. Pharmacological and interventional strategies for chronic Chagas cardiomyopathy: a systematic review of clinical outcomes. Rev Clin Esp (Barc). 2026;226(6):502546. doi:10.1016/j.rceng.2026.502546
11. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
12. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190
13. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-67. doi:10.1016/S0140-6736(22)01429-5
14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368
15. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi:10.1093/eurheartj/ehad195
16. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
17. Marcondes-Braga FG, Moura LAZ, Issa VS, Vieira JL, Rohde LE, Simões MV, et al. Emerging topics update of the Brazilian Heart Failure Guideline – 2021. Arq Bras Cardiol. 2021;116(6):1174-212. doi:10.36660/abc.20210367
18. Bocchi EA, Echeverria LE, Demacq C, de Barros E Silva PGM, Mazza Barbosa L, Chiang LM, et al. Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy: rationale and design of the PARACHUTE-HF trial. JACC Heart Fail. 2024;12(8):1473-86. doi:10.1016/j.jchf.2024.05.021
19. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi:10.1186/s41073-019-0064-8
20. Gómez-Ochoa SA, Rojas LZ, Echeverría LE. Winding down the storm: could empagliflozin's ion-dependent mechanisms tackle the ventricular arrhythmia burden in chronic Chagas cardiomyopathy? Cardiovasc Drugs Ther. 2024;38(1):203-5. doi:10.1007/s10557-023-07510-8
21. Echeverría LE, Rojas LZ, Serrano-García AY, Botero D, García-Rueda KA, Torres-Bustamante Á, et al. Prescription of medical therapy and postdischarge outcomes in patients hospitalized with HFrEF: insights from the ICARUS registry. Rev Esp Cardiol (Engl Ed). 2026. Epub ahead of print. doi:10.1016/j.rec.2026.08.006
22. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61. doi:10.1056/NEJMoa2107038
23. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-98. doi:10.1056/NEJMoa2206286
24. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-29. doi:10.1016/S0140-6736(20)31824-9
25. Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, et al. Sacubitril/valsartan vs enalapril in heart failure due to Chagas disease: an open-label, multicenter randomized clinical trial. JAMA. 2026;335(1):49-59. doi:10.1001/jama.2025.19808
26. Madrini V, Souza PVR, Fernandes F, Ianni BM, Martins AS, Luzuriaga GJ, et al. Sacubitril-valsartan vs enalapril in heart failure due to Chagas disease: primary results of ANSWER-HF randomized trial. J Am Coll Cardiol. 2026;87(10):1220-32. doi:10.1016/j.jacc.2025.10.053
27. Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127. doi:10.1038/s41467-020-15983-6
28. Kang S, Verma S, Fatehi Hassanabad A, Teng G, Belke DD, Dundas JA, et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36(4):543-53. doi:10.1016/j.cjca.2019.08.033
29. Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188-204. doi:10.1161/CIRCULATIONAHA.121.053350
30. Silva Dos Santos D, Turaça LT, Coutinho KCDS, Barbosa RAQ, Polidoro JZ, Kasai-Brunswick TH, et al. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. Sci Rep. 2023;13(1):8689. doi:10.1038/s41598-023-35944-5
31. de Souza IIA, da Rosa CFM, Marinho LE, Coutinho MB, Moraes CDS, de Carvalho ACC, et al. Direct dapagliflozin exposure enhances respiration and membrane hyperpolarization in isolated cardiac mitochondria. Front Physiol. 2026;17:1716764. doi:10.3389/fphys.2026.1716764
32. Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol. 2022;110:109024. doi:10.1016/j.intimp.2022.109024
33. Lv C, Hu C, Zhu C, Wan X, Chen C, Ji X, et al. Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis. Biomed Pharmacother. 2023;170:115963. doi:10.1016/j.biopha.2023.115963
34. Sheng W, Yu J, Zhang H, Zhang J. Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation. Mol Immunol. 2024;167:43-52. doi:10.1016/j.molimm.2024.02.006
35. Yan P, Song X, Tran J, Zhou R, Cao X, Zhao G, et al. Dapagliflozin alleviates coxsackievirus B3-induced acute viral myocarditis by regulating the macrophage polarization through Stat3-related pathways. Inflammation. 2022;45(5):2078-90. doi:10.1007/s10753-022-01677-2
36. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109-23. doi:10.1161/CIRCULATIONAHA.106.624296
37. Maldonado E, Rojas DA, Urbina F, Solari A. The oxidative stress and chronic inflammatory process in Chagas disease: role of exosomes and contributing genetic factors. Oxid Med Cell Longev. 2021;2021:4993452. doi:10.1155/2021/4993452
38. Lopez M, Tanowitz HB, Garg NJ. Pathogenesis of chronic Chagas disease: macrophages, mitochondria, and oxidative stress. Curr Clin Microbiol Rep. 2018;5(1):45-54. PMID: 29868332
39. Wen JJ, Garg NJ. Manganese superoxide dismutase deficiency exacerbates the mitochondrial ROS production and oxidative damage in Chagas disease. PLoS Negl Trop Dis. 2018;12(7):e0006687. doi:10.1371/journal.pntd.0006687
40. Nagajyothi JF, Weiss LM. Advances in understanding the role of adipose tissue and mitochondrial oxidative stress in Trypanosoma cruzi infection. F1000Res. 2019;8:F1000 Faculty Rev-1152. doi:10.12688/f1000research.19190.1
41. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J. 1990;120(1):233-6. doi:10.1016/0002-8703(90)90191-y
42. Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, et al. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. J Am Coll Cardiol. 2018;72(21):2577-87. doi:10.1016/j.jacc.2018.08.2195
43. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006;355(8):799-808. doi:10.1056/NEJMoa053241
44. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632-44. doi:10.1016/j.jacbts.2020.02.004
45. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243-55. doi:10.1016/j.jacc.2020.11.008
46. Karsa MG, Rahma V, Iqhramullah M, Habiburrahman M. Effect of sodium-glucose cotransporter-2 inhibitors on electrocardiographic markers of ventricular repolarization: a systematic review and meta-analysis. Am Heart J Plus. 2026;70:100888. doi:10.1016/j.ahjo.2026.100888
47. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727-38. doi:10.1093/eurheartj/ehab560
48. Oates CP, Santos-Gallego CG, Smith A, Basyal B, Moss N, Kawamura I, et al. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials. J Cardiovasc Electrophysiol. 2023;34(5):1277-85. doi:10.1111/jce.15894
49. Liao J, Ebrahimi R, Ling Z, Meyer C, Martinek M, Sommer P, et al. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death). Cardiovasc Diabetol. 2024;23(1):78. doi:10.1186/s12933-024-02137-x
50. Lin M, Zhang S, Zhang L, Yang C, Luo Y, Peng Y, et al. Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials. Syst Rev. 2025;14(1):31. doi:10.1186/s13643-025-02766-7
51. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146(18):1383-405. doi:10.1161/CIRCULATIONAHA.122.061732
52. Vilar-Pereira G, Carneiro VC, Mata-Santos H, Vicentino ARR, Ramos IP, Giarola NLL, et al. Resveratrol reverses functional Chagas heart disease in mice. PLoS Pathog. 2016;12(10):e1005947. doi:10.1371/journal.ppat.1005947
53. Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5(2):169-79. doi:10.1016/j.jacbts.2019.11.007
54. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care. 2016;39(7):1108-14. doi:10.2337/dc16-0330
55. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
56. Echeverria LE, Bocchi E, Demacq C, de Barros E Silva PGM, Chiang LM, Sayyed S, et al. Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: baseline characteristics of the PARACHUTE-HF trial. Eur J Heart Fail. 2025;27(12):2879-86. doi:10.1002/ejhf.70026
57. Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020;41(36):3402-18. doi:10.1093/eurheartj/ehaa496
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Francisco Rodrigo de Asevedo Mendes de Oliveira, Itala de Oliveira Vitoriano Mendes, Tâmara Nascimento Lima, Erik Douglas Oliveira de Souza, Kamily Alves Mendes dos Santos, Maria Antonia Nel Sousa, Lucas Rabelo Ferreira, Daniel Mendes Sampaio Lopes, Juscelino Vieira Gonçalves Junior, Gedayan Almeida da Silva, Matheus Silva Brito, Paulo Henrique Pontili Vasconcelos

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.



